Alimera Sciences Inc (ALIM)

1.49
NASDAQ : Health Care
Prev Close 1.49
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.01 / 5.15
Avg Volume 939.40K
Exchange NASDAQ
Shares Outstanding 45.76M
Market Cap 70.93M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

April 2017 Options Now Available For Alimera Sciences (ALIM)

April 2017 Options Now Available For Alimera Sciences (ALIM)

Investors in Alimera Sciences, Inc. saw new options become available today, for the April 2017 expiration.

Alimera (ALIM) Is Today's Strong On High Volume Stock

Alimera (ALIM) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Alimera (ALIM) as a strong on high relative volume candidate

Weak On High Volume: Alimera (ALIM)

Weak On High Volume: Alimera (ALIM)

Trade-Ideas LLC identified Alimera (ALIM) as a weak on high relative volume candidate

Insider Trading Alert - VLGEA, LLTC And ALIM Traded By Insiders

Insider Trading Alert - VLGEA, LLTC And ALIM Traded By Insiders

Stocks with insider trader activity include VLGEA, LLTC and ALIM

Short Interest In Alimera Sciences Makes 15% Move

Short Interest In Alimera Sciences Makes 15% Move

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 314,613 share increase in total short interest for Alimera Sciences, Inc. , to 2,422,062, an increase of 14.93% since 01/15/2016.

Short Interest In Alimera Sciences Jumps 14.2%

Short Interest In Alimera Sciences Jumps 14.2%

The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, which shows a 261,657 share increase in total short interest for Alimera Sciences, Inc. , to 2,107,449, an increase of 14.18% since 12/31/2015.

Short Interest In Alimera Sciences Decreases By 17.4%

Short Interest In Alimera Sciences Decreases By 17.4%

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 387,663 share decrease in total short interest for Alimera Sciences, Inc. , to 1,845,792, a decrease of 17.36% since 12/15/2015.

Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active

Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active

The CMS reimbursement code for ILUVIEN® is expected to ease and speed insurance payments

Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN® Slows Diabetic Retinopathy Progression

Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN® Slows Diabetic Retinopathy Progression

Data presented as Late Breaking Development during Retina Subspecialty Day at AAO 2015

Alimera Sciences To Speak At Ophthalmology Innovation Summit 2015

Alimera Sciences To Speak At Ophthalmology Innovation Summit 2015

Dan Myers, CEO, will join leading innovators in ophthalmology to discuss ILUVIEN® and advancements in the industry